Opdivo replaces Nivolumab BMS for treatment of lung cancer

Opdivo (nivolumab) is now indicated in the treatment of locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) after prior chemotherapy, in addition to its original indication in melanoma.

Nivolumab was originally launched for the treatment of NSCLC as Nivolumab BMS, but the manufacturer has now reconciled both indications under the Opdivo brand name. The two brands contain identical presentations of nivolumab and the same dosage regimen is used in both types of cancer.

The discontinuation of Nivolumab BMS will have no impact on patients with lung cancer already being prescribed nivolumab, other than a change in the brand name of their treatment. 

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

A woman leans on a desk holding her stomach in pain.

Draft NICE approval for new fibroid treatment

Around 4500 women in England and Wales will be eligible...

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

New products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products added...

Drug price changes - live tracker

EXCLUSIVE TO SUBSCRIBERS Use our constantly updated...